ERBB2 and breast cancer: Although the underlying mechanisms for the clinical efficacy of adjuvant trastuzumab in HER2-negative breast cancer are still unclear, it has been proposed that cancer stem cells might be involved in the molecular subtype conversion from HER2-negative tumors to HER2-positive tumors [9, 10].